Reata gives Abbvie something else to think about
As the final cohort in the Phoenix trial reads out positively for bardoxolone the stage is set for pivotal results and a decision by Abbvie.
Hope on the horizon for rare kidney disease
Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking…
Mid-cap investors see Eastern promise in the third quarter
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
Upcoming events – Phase II readouts loom for Concert and Reata
Concert hopes to give Pfizer a run for its money in alopecia, while Reata looks to continue its renaissance with more Phoenix data.
Reata gets full marks for perseverance and biz dev nous
Reata's unexpected success in kidney disease could see Abbvie paying out yet more licensing cash.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.